Vivantes Klinikum am Urban | Vivantes Klinikum am Urban Hämatologie und Onkologie

Research site
Dieffenbachstrasse 1, Berlin, Berlin, Germany
Site insights

Top conditions

Atrial Fibrillation (7 trials)

Lymphoma (7 trials)

Prostatic Cancer (5 trials)

Myeloid Leukemia (4 trials)

Acute Myeloid Leukemia (4 trials)

Top treatments


Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site


13 of 46
Status: Active
Trial type: Interventional
Funder type: Industry

A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in R/R DLBCL (EPCORE DLBCL-1)

The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Polatuzumab vedotin Placebo
Drug: Vincristine Placebo

The main purpose of this study is to determine if the addition of apalutamide to radiotherapy (RT) plus luteinizing hormone-releasing hormone agonist...

Prostatic Neoplasms
Radiation: Radiotherapy
Drug: LHRHa

The purpose of this study is to evaluate efficacy of erdafitinib versus chemotherapy or pembrolizumab in participants with advanced urothelial cancer...

Active, not recruiting
Urothelial Cancer
Drug: Erdafitinib
Drug: Vinflunine

The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS)...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

The purpose of the study is to compare the efficacy of zanubrutinib plus obinutuzumab versus lenalidomide plus rituximab (R^2) in participants with r...

Relapsed/Refractory Follicular Lymphoma
Marginal Zone Lymphoma
Drug: Rituximab
Drug: Zanubrutinib

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Biochemically Recurrent Prostate Cancer
Other: Placebo matching darolutamide
Drug: Darolutamide (BAY1841788, Nubeqa)

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Rituximab

In Waldenström macroglobulinemia (WM) chemotherapy induces only low CR/VGPR (Complete Remission/ Very Good Partial Response) rates and responses of s...

Waldenstrom Macroglobulinemia
Drug: Ibrutinib
Drug: Carfilzomib + Ibrutinib

This will be a confirmatory, prospective, open-label, single-arm, reader-blinded, multi-centre phase 3 study to assess the diagnostic accuracy and sa...

Drug: Ferrotran® (Ferumoxtran-10)

This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreat...

Active, not recruiting
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Drug: zanubrutinib
Drug: bendamustine

This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoc...

Active, not recruiting
Mantle-Cell Lymphoma
Drug: Ibrutinib
Drug: Venetoclax

The trial is a randomized, open-label phase III study comparing CPX-351 vs conventional intensive induction and consolidation chemotherapy in patient...

Acute Myeloid Leukemia
Drug: Cytarabine
Drug: CPX-351

Trial sponsors

Boston Scientific logo

Boston Scientific (3 trials)

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems